Company Overview and News
Stop missing out on important events!
Chimeric antigen receptor T-cell receptor (CAR-T) and CAR-modified natural killer (CAR-NK) therapeutics can be produced faster and at less cost, Cesca Therapeutics says, through the cellular processing technology covered by a recently-awarded patent.
LONDON, UK / ACCESSWIRE / July 31, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Cesca Therapeutics Inc. (NASDAQ: KOOL) ("Cesca"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=KOOL. The Company, which is a market leader in automated cell processing, announced on July 28, 2017, that the US Patent and Trademark Office has awarded a new US Patent (the ‘394 patent'), entitled Cell Separation Devices, Systems, and Methods to SynGen, Inc.
LONDON, UK / ACCESSWIRE / July 12, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Cesca Therapeutics Inc. (NASDAQ: KOOL), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=KOOL. The Company announced on July 10, 2017, that its wholly-owned subsidiary, ThermoGenesis Corp., has entered into an asset acquisition agreement with SynGen, Inc.
• Shares of Hawaiian Telcom Holdco, Inc. surged 18.1% following news that Cincinnati Bell (CBB - Free Report) has decided to acquire the company for $650 million • Cesca Therapeutics Inc's soared 16.9% after the company purchased SynGen Inc.’s cell processing systems • Shares of ClubCorp Holdings, Inc. (MYCC - Free Report) skyrocketed 30.2% following news that Apollo Global Management (APO - Free Report) has agreed to acquire the company for $1.
WASHINGTON, DC--(Marketwired - May 9, 2017) - The Alliance for Regenerative Medicine (ARM) today released the agenda for the inaugural Cell & Gene Exchange, the only partnering conference that brings together the regulatory, business and patient advocacy communities across the cell and gene therapy sectors. Co-produced by ARM and EBD Group and held in partnership with Global Genes, the event will take place May 22 and 23 in Washington, D.